Saltar al contenido
Merck

Documentos clave

Ver Toda la documentación

Saltar a

SML2261

Conivaptan hydrochloride

≥98% (HPLC)

Sinónimos:

N-[4-[(4,5-dihydro-2­methylimidazo[4,5-d][1]benzazepin-6(1H)-yl)carbonyl]phenyl]- [1,1’-biphenyl]-2-carboxamide monohydrochloride

Iniciar sesión para ver los precios por organización y contrato.

Seleccione un Tamaño

Cambiar Vistas
Tamaño de envaseSKUDisponibilidadPrecio
10 mg
Comprobar disponibilidad del carrito
$55.100
50 mg
Comprobar disponibilidad del carrito
$227.000

Acerca de este artículo

Fórmula empírica (notación de Hill):
C32H26N4O2 · HCl
Número CAS:
168626-94-6
Peso molecular:
535.04
UNSPSC Code:
12352200
NACRES:
NA.77
MDL number:
MFCD00945712
Assay:
≥98% (HPLC)
Form:
powder
Storage condition:
desiccated

$55.100

Comprobar disponibilidad del carrito
​
Solicite una orden a granel
Servicio técnico
¿Necesita ayuda? Nuestro equipo de científicos experimentados está aquí para ayudarle.
Permítanos ayudarle

assay

≥98% (HPLC)

form

powder

storage condition

desiccated

color

white to beige

solubility

DMSO: 2 mg/mL, clear

storage temp.

2-8°C

SMILES string

O=C(NC1=CC=C(C(N2CCC(N=C(C)N3)=C3C4=C2C=CC=C4)=O)C=C1)C5=CC=CC=C5C6=CC=CC=C6.Cl

InChI

1S/C32H26N4O2.ClH/c1-21-33-28-19-20-36(29-14-8-7-13-27(29)30(28)34-21)32(38)23-15-17-24(18-16-23)35-31(37)26-12-6-5-11-25(26)22-9-3-2-4-10-22;/h2-18H,19-20H2,1H3,(H,33,34)(H,35,37);1H

InChI key

BTYHAFSDANBVMJ-UHFFFAOYSA-N

Biochem/physiol Actions

Conivaptan hydrochloride is a novel dual Arginine vasopressin receptor (AVP-R) antagonist for AVP-R types 1a (V1a) and V2-R. Conivaptan potently inhibits AVP-induced intracellular signaling through human V2 and V1a receptors with no agonistic activity.
Nonpeptide, dual vasopressin V1a/V2 receptor antagonist

Comparar elementos similares

Ver comparación completa

Mostrar Diferencias

1 of 1

Este artículo
SML2114SML1947SML2761
Conivaptan hydrochloride ≥98% (HPLC)

Sigma-Aldrich

SML2261

Conivaptan hydrochloride

ZD7155 hydrochloride ≥97% (HPLC)

Sigma-Aldrich

SML2114

ZD7155 hydrochloride

ITH12575 ≥98% (HPLC)

Sigma-Aldrich

SML1947

ITH12575

SGC6870N ≥98% (HPLC)

Sigma-Aldrich

SML2761

SGC6870N

form

powder

form

powder

form

powder

form

powder

assay

≥98% (HPLC)

assay

≥97% (HPLC)

assay

≥98% (HPLC)

assay

≥98% (HPLC)

storage temp.

2-8°C

storage temp.

2-8°C

storage temp.

2-8°C

storage temp.

2-8°C

storage condition

desiccated

storage condition

desiccated

storage condition

-

storage condition

-

solubility

DMSO: 2 mg/mL, clear

solubility

H2O: 2 mg/mL, clear (warmed)

solubility

DMSO: 2 mg/mL, clear

solubility

DMSO: 2 mg/mL, clear

color

white to beige

color

white to beige

color

white to beige

color

white to beige

pictograms

Health hazard
GHS08

signalword

Warning

hcodes

H361fd

Hazard Classifications

Repr. 2

Clase de almacenamiento

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Elija entre una de las versiones más recientes:

Certificados de análisis (COA)

Lot/Batch Number
0000282947
0000282947
0000125561
0000111451
0000045006

¿No ve la versión correcta?

Si necesita una versión concreta, puede buscar un certificado específico por el número de lote.

Busque por un COA

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Yukinori Arai et al.
Journal of pharmacological sciences, 109(1), 53-59 (2009-01-20)
Hyponatremia is the most common electrolyte disorder in hospitalized patients and is associated with the risk of intractable seizures and death. The effectiveness of conventional therapies for hyponatremia is inconsistent, and the rapid correction of plasma sodium levels is thought
A Tahara et al.
The Journal of pharmacology and experimental therapeutics, 282(1), 301-308 (1997-07-01)
The biochemical and pharmacological profile of YM087, 4'-[(2-methyl-1,4,5,6-tetrahydroimidazo[4,5-d][1]benzazepin- 6-yl)-carbonyl]-2-phenylbenzanilide monohydrochloride, a newly synthesized nonpeptide vasopressin (AVP) antagonist, was investigated in several in vitro and in vivo studies. YM087 showed high affinity for V1A receptors from rat liver and V2 receptors
Poornima Vinod et al.
Cardiology research, 8(3), 87-95 (2017-07-21)
Heart and kidney failure continued to be of increasing prevalence in today's society, and their comorbidity has synergistic effect on the morbidity and mortality of patients. Cardiorenal syndrome (CRS) is a complex disease with multifactorial pathophysiology. Better understanding of this

Número de artículo de comercio global

SKUGTIN
SML2261-50MG04061835496563
SML2261-10MG04061835496556

Questions

Reviews

No rating value

Active Filters